Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma

Key Takeaway: Novocure has announced topline data from the Phase 3 TRIDENT trial, which evaluates the earlier use of Tumor Treating Fields therapy in patients with newly diagnosed glioblastoma. The results are expected to provide insights into the therapy's effectiveness in this patient population. Further details on the outcomes and implications of the trial have yet to be disclosed.